- Heron Therapeutics (NASDAQ:HRTX) on Tuesday said that the U.S. Food and Drug Administration (FDA) had acknowledged the receipt of the company’s prior approval supplement application for Zynrelef extended-release solution VAN.
- The company added that the FDA has assigned a PDUFA date of September 23, 2024.
- Press release.
2024-07-02